Received Mar 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | UNK | — | — |
"The HCP sttated she did not experienced any other adverse issues ir side effects form the administered or missed dose"; No adverse event; Information has been received from Business Partner/CRO on 28-Feb-2025. This spontaneous report was received from a/an Other health professional and refers to a(n) 51-year-old female patient. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On Sep-1978, the patient started therapy with Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II), (lot # and expiration date were not reported). On an unknown date, the patient started therapy with sterile diluent (BAXTER STERILE DILUENT), (indication, expiration date, and lot # were not reported). The patient started therapy with Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II), for the treatment of Prophylaxis. On an unknown date, the patient experienced No adverse event. On an unknown date, the patient experienced "The HCP sttated she did not experienced any other adverse issues ir side effects form the administered or missed dose". At the reporting time, the outcome of No adverse event and "The HCP sttated she did not experienced any other adverse issues ir side effects form the administered or missed dose" was unknown. The action taken with Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live and sterile diluent was reported as not applicable.
Sterile diluent